Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment

BMC Neurology

Volumn 15, Issue 1, 2015, Pages

  Dugger, Brittany N ^a   Davis, Kathryn ^a   Malek Ahmadi, Michael ^a   Hentz, Joseph G ^b   Sandhu, Shawn ^a   Beach, Thomas G ^a   Adler, Charles H ^b   Caselli, Richard J ^b   Johnson, Travis A ^b   Serrano, Geidy E ^a   Shill, Holly A ^a   Belden, Christine ^a   Driver Dunckley, Erika ^b   Caviness, John N ^b   Sue, Lucia I ^a   Jacobson, Sandra ^a   Powell, Jessica ^a   Sabbagh, Marwan N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

AGE; AGED; APOE4 GENE; ARTICLE; AUTOPSY; BRAIN DISEASE; BRAIN INFARCTION; CEREBRAL WHITE MATTER RAREFACTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HETEROZYGOTE; HUMAN; LEWY BODY; MALE; MILD COGNITIVE IMPAIRMENT; MOTOR NEURON DISEASE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PARIETAL LOBE; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; SENILE PLAQUE; SHY DRAGER SYNDROME; TEMPORAL LOBE; VASCULAR AMYLOIDOSIS; VERY ELDERLY; AMNESIA; AMYLOID PLAQUE; BRAIN; COGNITIVE DEFECT; COMPLICATION; LEUKOENCEPHALOPATHY; PATHOLOGY;

AGED; AGED, 80 AND OVER; AMNESIA; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL INFARCTION; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; LEUKOENCEPHALOPATHIES; LEWY BODIES; MALE; NEUROFIBRILLARY TANGLES; PARKINSON DISEASE; PLAQUE, AMYLOID; TEMPORAL LOBE;

EID: 84939521880     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-015-0403-4     Document Type: Article

References (38)

1. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-94. doi: 10.1111/j.1365-2796.2004.01388.x .
2. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41(7):1006-9.
3. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-6. doi: 10.1111/j.1365-2796.2004.01380.x .
4. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement. 2011;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008 .
5. Saito Y, Murayama S. Neuropathology of mild cognitive impairment. Neuropathology. 2007;27(6):578-84. doi: 10.1111/j.1440-1789.2007.00806.x .
6. Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimer Dis. 2010;19(1):221-8. doi: 10.3233/JAD-2010-1220 .
7. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006;63(1):38-46. doi: 10.1001/archneur.63.1.38 .
8. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834-41. doi: 10.1212/01.WNL.0000152982.47274.9E .
9. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63(5):665-72. doi: 10.1001/archneur.63.5.665 .
10. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200-8. doi: 10.1002/ana.21706 .
11. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674-81. doi: 10.1001/archneur.63.5.674 .
12. Ferman TJ, Smith GE, Kantarci K, Boeve BF, Pankratz VS, Dickson DW, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013;81(23):2032-8. doi: 10.1212/01.wnl.0000436942.55281.47 .
13. Galvin JE, Powlishta KK, Wilkins K, McKeel Jr DW, Xiong C, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005;62(5):758-65. doi: 10.1001/archneur.62.5.758 .
14. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, et al. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank. 2008;9(3):229-45. doi: 10.1007/s10561-008-9067-2 .
15. Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG, et al. Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology. 2015;35:354-89. doi: 10.1111/neup.12189 .
16. Ellison D. Neuropathology: a reference text of CNS pathology. 2nd ed. Edinburgh, New York: Mosby; 2004.
17. Dugger BN, Hentz JG, Adler CH, Sabbagh MN, Shill HA, Jacobson S, et al. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol. 2014;73(3):244-52. doi: 10.1097/NEN.0000000000000046 .
18. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545-8.
19. Beach TG, Sue LI, Walker DG, Sabbagh MN, Serrano G, Dugger B, et al. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J Alzheimers Dis. 2011;28:869-76. doi: 10.3233/JAD-2011-111340 .
20. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1(3):213-6.
21. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathologica. 2009;117(6):613-34. doi: 10.1007/s00401-009-0538-8 .
22. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathologica. 2008;116(3):277-88. doi: 10.1007/s00401-008-0409-8 .
23. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479-86.
24. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997;18(4 Suppl):S1-2.
25. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica. 1991;82(4):239-59.
26. Dugger BN, Clark CM, Serrano G, Mariner M, Bedell BJ, Coleman RE, et al. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol. 2014;73(1):72-80. doi: 10.1097/NEN.0000000000000028 .
27. Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN, et al. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord. 2009;23(3):229-33. doi: 10.1097/WAD.0b013e318199d833 .
28. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-204. doi: 10.1212/01.wnl.0000271090.28148.24 .
29. Adler CH, Caviness JN, Sabbagh MN, Shill HA, Connor DJ, Sue L, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathologica. 2010;120(6):827-8. doi: 10.1007/s00401-010-0744-4 .
30. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60(5):729-36. doi: 10.1001/archneur.60.5.729 .
31. Sabbagh MN, Shah F, Reid RT, Sue L, Connor DJ, Peterson LK, et al. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol. 2006;63(12):1771-6. doi: 10.1001/archneur.63.12.1771 .
32. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062-9. doi: 10.1212/WNL.0b013e3181f39d0e .
33. White L, Launer L. Relevance of cardiovascular risk factors and ischemic cerebrovascular disease to the pathogenesis of Alzheimer disease: a review of accrued findings from the Honolulu-Asia Aging Study. Alzheimer Dis Assoc Disord. 2006;20(3 Suppl 2):S79-83.
34. Hirono N, Kitagaki H, Kazui H, Hashimoto M, Mori E. Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study. Stroke. 2000;31(9):2182-8.
35. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med. 2003;9(3-4):112-22.
36. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology. 2005;64(3):494-500. doi: 10.1212/01.WNL.0000150886.50187.30 .
37. Devine ME, Fonseca JA, Walker Z. Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia? Int Psychogeriatr. 2013;25(1):120-7. doi: 10.1017/S1041610212000932 .
38. Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr. 2008;13(1):45-53.